ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software
https://www.zacks.com/stock/news/2231836/clearpoint-neuro-clpt-gets-fda-s-nod-for-new-software?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2231836
Feb 26, 2024 - ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.
0
2 No-Brainer Healthcare Stocks to Buy Right Now
https://www.fool.com/investing/2024/02/10/2-no-brainer-healthcare-stocks-to-buy-right-now/?source=iedfolrf0000001
Feb 10, 2024 - Companies in the healthcare industry tend to generate returns in a wide range of market environments.
0
DexCom (DXCM) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/02/08/dexcom-dxcm-q4-2023-earnings-call-transcript/?source=iedfolrf0000001
Feb 08, 2024 - DXCM earnings call for the period ending December 31, 2023.
0
DexCom (DXCM) Reports Q4 Earnings: What Key Metrics Have to Say
https://www.zacks.com/stock/news/2223683/dexcom-dxcm-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2223683
Feb 08, 2024 - The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Curious about DexCom (DXCM) Q4 Performance? Explore Wall Street Estimates for Key Metrics
https://www.zacks.com/stock/news/2220910/curious-about-dexcom-dxcm-q4-performance-explore-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2220910
Feb 05, 2024 - Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
0
DexCom (DXCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
https://www.zacks.com/stock/news/2219585/dexcom-dxcm-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2219585
Feb 01, 2024 - DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Intuitive Surgical (ISRG) Seeks FDA Nod for Next-Gen da Vinci 5
https://www.zacks.com/stock/news/2216520/intuitive-surgical-isrg-seeks-fda-nod-for-next-gen-da-vinci-5?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2216520
Jan 26, 2024 - Intuitive Surgical (ISRG) aims to boost its da Vinci portfolio with the addition of its next-generation da Vinci 5 multiport surgical robot.
0
DexCom (DXCM) Stock Declines While Market Improves: Some Information for Investors
https://www.zacks.com/stock/news/2214611/dexcom-dxcm-stock-declines-while-market-improves-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2214611
Jan 23, 2024 - DexCom (DXCM) concluded the recent trading session at $127.12, signifying a -1.68% move from its prior day's close.
0
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
https://www.zacks.com/stock/news/2212771/reasons-to-retain-dexcom-dxcm-stock-in-your-portfolio-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2212771
Jan 19, 2024 - DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
0
DexCom (DXCM) Crossed Above the 20-Day Moving Average: What That Means for Investors
https://www.zacks.com/stock/news/2212075/dexcom-dxcm-crossed-above-the-20-day-moving-average-what-that-means-for-investors?cid=CS-ZC-FT-tale_of_the_tape|20_day_moving_average_(yseop)-2212075
Jan 18, 2024 - Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
0